您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Lansoprazole-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Lansoprazole-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Lansoprazole-d4图片
CAS NO:934294-22-1
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
Lansoprazole D4 (AG-1749 D4) 是一种氘标记的兰索拉唑。
Cas No.934294-22-1
别名兰索拉唑-D4,AG-1749-d4
Canonical SMILESCC1=C(CS(C2=NC(C([2H])=C([2H])C([2H])=C3[2H])=C3N2)=O)N=CC=C1OCC(F)(F)F
分子式C16H10D4F3N3O2S
分子量373.4
溶解度DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 5 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Lansoprazole-d4is intended for use as an internal standard for the quantification of lansoprazole by GC- or LC-MS. Lansoprazole is a proton pump inhibitor that inhibits the H+/K+-ATPase.1It inhibits K+and H+accumulation in gastric microsomes in a concentration-dependent manner (IC50s = 6.3 and 7 µM, respectively) and inhibits H+/K+-ATPase activity by approximately 60% when used at a concentration of 10 µM. Lansoprazole inhibits the H+/K+-ATPase in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH.2It is a substituted benzimidazole that binds covalently to proton pumps, providing complete and prolonged inhibition of acid secretion.3,4Formulations containing lansoprazole have been used as a proton pump inhibitor and in combination with antibiotics in the treatment ofH. pyloriinfections and duodenal ulcer disease.

1.Nagaya, H., Satoh, H., Kubo, K., et al.Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749J. Pharmacol. Exp. Ther.248(2)799-805(1989) 2.Schubert, M.L.Pharmacotherapy for acid/peptic disordersYale J. Biol. Med.69(2)197-201(1996) 3.Richardson, P., Hawkey, C.J., and Stack, W.A.Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disordersDrugs56(3)307-335(1998) 4.Klotz, U.Pharmacokinetic considerations in the eradication of Helicobacter pyloriClin. Pharmacokinet.38(3)243-270(2000)